Related Experiment Video

Updated: Jun 5, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Oliver Kepp1, Lorenzo Galluzzi, Isabelle Martins

  • 1INSERM, U848, Institut Gustave Roussy, Pavillon de Recherche 1, 94805 Villejuif (Paris), France.

Cancer Metastasis Reviews
|January 21, 2011
PubMed

Insights

Chemo- and radiotherapy success depends on immunogenic cell death, which signals immune cells to target cancer. Key proteins like calreticulin, ATP, and HMGB1 released by dying cells trigger this crucial anticancer immune response.

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Chemo- and radiotherapy efficacy is linked to inducing immunogenic cell death (ICD).
  • ICD involves specific cellular changes and the release of pro-immunogenic factors.
  • This process is crucial for stimulating an anticancer immune response, potentially targeting therapy-resistant cells.

Purpose of the Study:

  • To review the molecular factors that determine if cell death is immunogenic.
  • To discuss the roles of calreticulin, ATP, and HMGB1 in ICD.

Main Methods:

  • Literature review focusing on molecular mechanisms of ICD.
  • Analysis of the role of specific proteins and molecules in immune cell stimulation.

Main Results:

  • Specific surface modifications and factor release characterize ICD.
  • Calreticulin, ATP, and HMGB1 are identified as key determinants of ICD.
  • These factors stimulate antigen-presenting cells to initiate a tumor-specific immune response.

Conclusions:

  • The molecular identity of factors released during cell death dictates its immunogenicity.
  • Calreticulin, ATP, and HMGB1 play critical roles in ICD and subsequent anticancer immunity.
  • Understanding these factors can enhance cancer therapeutic strategies.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...